Medroxyprogesterone instructions for administration

Revision as of 14:40, 20 December 2011 by Matt Pijoan (talk | contribs) (Reverted edits by Puwok2008mlA7 (talk) to last revision by NNethala)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Instructions for administration

Vasomotor Symptoms / Vulvar and Vaginal Atrophy

Postmenopausal Osteoporosis



Vasomotor Symptoms / Vulvar and Vaginal Atrophy

Patients should be treated with the lowest effective dose. Generally women should be started at 0.3 mg/1.5 mg PREMPRO daily. Subsequent dosage adjustment may be made based upon the individual patient response. In patients where bleeding or spotting remains a problem, after appropriate evaluation, consideration should be given to changing the dose level. This dose should be periodically reassessed by the healthcare provider. Return to top

Postmenopausal Osteoporosis

Patients should be treated with the lowest effective dose. Generally women should be started at 0.3 mg/1.5 mg PREMPRO daily. Dosage may be adjusted depending on individual clinical and bone mineral density responses. This dose should be periodically reassessed by the healthcare provider. In patients where bleeding or spotting remains a problem, after appropriate evaluation, consideration should be given to changing the dose level. This dose should be periodically reassessed by the healthcare provider. PREMPHASE therapy consists of two separate tablets; one maroon 0.625 mg Premarin tablet taken daily on days 1 through 14 and one light-blue tablet, containing 0.625 mg conjugated estrogens and 5 mg of medroxyprogesterone acetate, taken on days 15 through 28. Return to top



Adapted from the FDA Package Insert.